Hologic
HOLX
#1289
Rank
ยฃ12.53 B
Marketcap
ยฃ56.23
Share price
0.15%
Change (1 day)
-7.09%
Change (1 year)
Categories
Hologic, Inc. is an American medical technology company primarily focused on womenโ€™s health, the company sells medical devices for diagnostics, surgery, and medical imaging.

P/E ratio for Hologic (HOLX)

P/E ratio as of December 2025 (TTM): 30.0

According to Hologic's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 29.994. At the end of 2024 the company had a P/E ratio of 22.7.

P/E ratio history for Hologic from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202422.7-32.74%
202333.777.95%
202218.965.99%
202111.4-16.5%
202013.7-75.66%
201956.1-304.89%
2018-27.4-347.4%
201711.1-67.15%
201633.7-42.49%
201558.6-60.54%
2014149
2012-58.9

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Thermo Fisher Scientific
TMO
33.1 10.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Becton Dickinson
BDX
35.0 16.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Boston Scientific
BSX
51.6 72.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
15.5-48.17%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
37.5 25.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Philips
PHG
118 293.90%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
Quest Diagnostics
DGX
21.2-29.40%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
19.4-35.41%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.